MARLBOROUGH, Mass.--(BUSINESS WIRE)--Cytyc Corporation (Nasdaq: CYTC) today announced results for the first quarter ended March 31, 2007. Revenue for the quarter ended March 31, 2007 rose 20 percent to $168.9 million compared to revenue of $140.5 million for the same period of 2006. Cytyc reported a net loss for the quarter of $(51.2) million, or $(0.45) per diluted share, reflecting in-process R&D charges totaling $89.5 million related to the acquisitions of Adeza Biomedical Corporation (“Adeza”), and Adiana Incorporated (“Adiana”). Excluding these charges, adjusted net income was $38.3 million, or $0.32 per diluted share. This compares with net income for the same period in 2006 of $29.4 million, or $0.24 per diluted share, a more than 30 percent increase. The Company’s cash balance at March 31, 2007 was $196.3 million.
